- Motley Fool•38 minutes ago
Wall Street has assigned some cheap valuations to The Greenbrier Companies, Alliance Resource Partners, and Gilead Sciences.
- Market Realist•1 hour ago
Besides its tenofovir alafenamide–based HIV drugs, Gilead Sciences expects solid uptake for its pre-exposure prophylaxis (or PrEP) HIV therapy, Truvada, in 2017.
- Market Realist•2 hours ago
Since its launch, Gilead's tenofovir alafenamide–based regimen, Genvoya, has managed to attain the status of the most prescribed regimen for all HIV groups treated in the United States.
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||69.25 x 200|
|Ask||69.26 x 1000|
|Day's Range||68.43 - 69.33|
|52 Week Range||65.38 - 103.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.95|
|Dividend & Yield||2.08 (3.00%)|
|1y Target Est||N/A|